194 related articles for article (PubMed ID: 26419617)
1. Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells.
Mirone G; Perna S; Shukla A; Marfe G
J Cell Physiol; 2016 May; 231(5):1097-105. PubMed ID: 26419617
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
Aprile G; Macerelli M; Giuliani F
BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872
[TBL] [Abstract][Full Text] [Related]
3. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
4. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.
Wei N; Chu E; Wu SY; Wipf P; Schmitz JC
Oncotarget; 2015 Mar; 6(7):4745-56. PubMed ID: 25544765
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor.
Tomida C; Nagano H; Yamagishi N; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
J Med Invest; 2017; 64(3.4):262-265. PubMed ID: 28954993
[TBL] [Abstract][Full Text] [Related]
6. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
Huynh H; Ong R; Zopf D
J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
Chen D; Wei L; Yu J; Zhang L
Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib in metastatic colorectal cancer.
Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
[TBL] [Abstract][Full Text] [Related]
14. The development of regorafenib and its current and potential future role in cancer therapy.
Davis SL; Eckhardt SG; Messersmith WA; Jimeno A
Drugs Today (Barc); 2013 Feb; 49(2):105-15. PubMed ID: 23462625
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
Wang YJ; Zhang YK; Zhang GN; Al Rihani SB; Wei MN; Gupta P; Zhang XY; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2017 Jun; 396():145-154. PubMed ID: 28302530
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
17. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
[TBL] [Abstract][Full Text] [Related]
18. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
Lippolis C; Refolo MG; D'Alessandro R; Carella N; Messa C; Cavallini A; Carr BI
J Exp Clin Cancer Res; 2015 Sep; 34(1):90. PubMed ID: 26329608
[TBL] [Abstract][Full Text] [Related]
19. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.
Camaj P; Primo S; Wang Y; Heinemann V; Zhao Y; Laubender RP; Stintzing S; Giessen-Jung C; Jung A; Gamba S; Bruns CJ; Modest DP
Future Oncol; 2015; 11(13):1919-29. PubMed ID: 26161928
[TBL] [Abstract][Full Text] [Related]
20. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]